Skip to Content

Eli Lilly and Co LLY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Coronavirus to Create $39 Billion Vaccine Market and $10 Billion Treatment Market in 2021

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Following a year with more than 83 million reported cases and 1.8 million reported deaths globally due to COVID-19, 2021 begins as two newly authorized vaccines are distributed to high-priority populations in the United States and Europe. These mRNA vaccines from Pfizer/BioNTech and Moderna have set a high bar for efficacy and safety, and they appear poised to ramp up supply and dominate the U.S. market throughout the first half of the year, supporting a foundation for herd immunity in the U.S. by midyear. With additional support from Johnson & Johnson, Novavax, AstraZeneca, and Chinese and Russian vaccine programs, global herd immunity looks achievable by 2023.

Read Full Analysis

Company Profile

Business Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
T +1 317 276-2000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Classic Growth
Employees 33,625

Related